SCHEMBL3195504

SCHEMBL3195504

O=c1c([N+](=O)[O-])c(Cl)ccn1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.50
HSPE1 P61604 1/20 0.50
RECQL P46063 1/20 0.49
MAPK14 Q16539 5/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.44
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 2/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
AGTR1 P30556 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3188133 0.84 HTT (0.52) HSPD1HSPE1RECQLMAPK14MEN1
SCHEMBL3195526 0.84 HSPD1 (0.46) HSPD1HSPE1RECQLMAPK14MEN1
SCHEMBL3190863 0.82 SMN1; SMN2 (0.47) RECQLMEN1KMT2AALDH1A1CYP1A2
SCHEMBL3203984 0.80 ALDH1A1 (0.44) HSPD1HSPE1RECQLMEN1KMT2A
SCHEMBL4064058 0.79 MAPK14 (0.65) HSPD1HSPE1MAPK14MEN1KMT2A
SCHEMBL15804003 0.75 RECQL (0.74) RECQLMEN1KMT2ALMNAHTT
SCHEMBL6837441 0.73 PTGER3 (0.46) MEN1KMT2ALMNAHTTALDH1A1
SCHEMBL13120826 0.73 ALDH1A1 (0.45) LMNAHTTALDH1A1SMN1; SMN2MAPT
SCHEMBL4478133 0.73 MAPK14 (0.52) MAPK14MEN1KMT2ALMNAHTT
SCHEMBL4145238 0.72 GAA (0.57) HSPD1HSPE1RECQLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678909-B1 2-[2-(3-Amino-cyclohexyl)-5-benzyl-4-oxo-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance; female infertility, osteoporosis, male contraception and neurological disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-16 US disclosed
US-7678909-B1 2-[2-(3-Amino-cyclohexyl)-5-benzyl-4-oxo-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance; female infertility, osteoporosis, male contraception and neurological disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-16 US disclosed
US-7678909-B1 2-[2-(3-Amino-cyclohexyl)-5-benzyl-4-oxo-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance; female infertility, osteoporosis, male contraception and neurological disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-16 US disclosed
US-7169926-B1 Dipeptidyl peptidase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-30 US disclosed
US-7169926-B1 Dipeptidyl peptidase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-30 US disclosed